Another immune checkpoint is mediated by binding of the ligands B7-1/2 (CD80, CD86) on activated antigen-presenting cells or cancer cells to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on T cells, which also suppresses T-cell activity [11,12]. The gene discussed is CD80; the disease is cancer.